Literature DB >> 31652307

Kelch-like protein 5-mediated ubiquitination of lysine 183 promotes proteasomal degradation of sphingosine kinase 1.

Jason A Powell1,2, Melissa R Pitman1, Julia R Zebol1, Paul A B Moretti1, Heidi A Neubauer1, Lorena T Davies1, Alexander C Lewis1, Laura F Dagley3,4, Andrew I Webb3,4, Maurizio Costabile1,5, Stuart M Pitson1,2,6.   

Abstract

Sphingosine kinase 1 (SK1) is a signalling enzyme that catalyses the phosphorylation of sphingosine to generate the bioactive lipid sphingosine 1-phosphate (S1P). A number of SK1 inhibitors and chemotherapeutics can induce the degradation of SK1, with the loss of this pro-survival enzyme shown to significantly contribute to the anti-cancer properties of these agents. Here we define the mechanistic basis for this degradation of SK1 in response to SK1 inhibitors, chemotherapeutics, and in natural protein turnover. Using an inducible SK1 expression system that enables the degradation of pre-formed SK1 to be assessed independent of transcriptional or translational effects, we found that SK1 was degraded primarily by the proteasome since several proteasome inhibitors blocked SK1 degradation, while lysosome, cathepsin B or pan caspase inhibitors had no effect. Importantly, we demonstrate that this proteasomal degradation of SK1 was enabled by its ubiquitination at Lys183 that appears facilitated by SK1 inhibitor-induced conformational changes in the structure of SK1 around this residue. Furthermore, using yeast two-hybrid screening, we identified Kelch-like protein 5 (KLHL5) as an important protein adaptor linking SK1 to the cullin 3 (Cul3) ubiquitin ligase complex. Notably, knockdown of KLHL5 or Cul3, use of a cullin inhibitor or a dominant-negative Cul3 all attenuated SK1 degradation. Collectively this data demonstrates the KLHL5/Cul3-based E3 ubiquitin ligase complex is important for regulation of SK1 protein stability via Lys183 ubiquitination, in response to SK1 inhibitors, chemotherapy and for normal SK1 protein turnover.
© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.

Entities:  

Keywords:  proteasome; protein degradation; protein turnover; sphingosine kinase; ubiquitin ligase

Year:  2019        PMID: 31652307     DOI: 10.1042/BCJ20190245

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  6 in total

1.  Sphingosine kinase 1 downregulation is required for adaptation to serine deprivation.

Authors:  Jean-Philip Truman; Christian F Ruiz; Magali Trayssac; Cungui Mao; Yusuf A Hannun; Lina M Obeid
Journal:  FASEB J       Date:  2021-02       Impact factor: 5.191

Review 2.  Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities.

Authors:  Victoria A Blaho
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

3.  A Novel Selective Sphingosine Kinase 2 Inhibitor, HWG-35D, Ameliorates the Severity of Imiquimod-Induced Psoriasis Model by Blocking Th17 Differentiation of Naïve CD4 T Lymphocytes.

Authors:  Sun-Hye Shin; Hee-Yeon Kim; Hee-Soo Yoon; Woo-Jae Park; David R Adams; Nigel J Pyne; Susan Pyne; Joo-Won Park
Journal:  Int J Mol Sci       Date:  2020-11-08       Impact factor: 5.923

4.  KLHL5 Is a Prognostic-Related Biomarker and Correlated With Immune Infiltrates in Gastric Cancer.

Authors:  Qiulin Wu; Guobing Yin; Jinwei Lei; Jiao Tian; Ailin Lan; Shengchun Liu
Journal:  Front Mol Biosci       Date:  2020-12-10

5.  The sphingosine 1-phosphate receptor 2/4 antagonist JTE-013 elicits off-target effects on sphingolipid metabolism.

Authors:  Melissa R Pitman; Alexander C Lewis; Lorena T Davies; Paul A B Moretti; Dovile Anderson; Darren J Creek; Jason A Powell; Stuart M Pitson
Journal:  Sci Rep       Date:  2022-01-10       Impact factor: 4.379

6.  Sphingosine Kinase 1 Regulates the Survival of Breast Cancer Stem Cells and Non-stem Breast Cancer Cells by Suppression of STAT1.

Authors:  Ling-Wei Hii; Felicia Fei-Lei Chung; Chun Wai Mai; Zong Yang Yee; Hong Hao Chan; Vijay Joseph Raja; Noah Elias Dephoure; Nigel J Pyne; Susan Pyne; Chee-Onn Leong
Journal:  Cells       Date:  2020-04-04       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.